27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Omega-3 polyunsaturated fatty acids (PUFAs) exhibit neuroprotective properties and represent a potential treatment for a variety of neurodegenerative and neurological disorders. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Mushrooms have been consumed since earliest history; ancient Greeks believed that mushrooms provided strength for warriors in battle, and the Romans perceived them as the "Food of the Gods." 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The neurone-centred view of the past disregarded or downplayed the role of astroglia as a primary component in the pathogenesis of neurological diseases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Probiotics actively participate in neuropsychiatric disorders. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The suprachiasmatic nucleus (SCN) of the hypothalamus, the master mammalian circadian pacemaker, synchronizes endogenous rhythms with the external day-night cycle. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The glucose transporter GLUT1 at the blood-brain barrier (BBB) mediates glucose transport into the brain. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cholesterol is an essential component for neuronal physiology not only during development stage but also in the adult life. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Oxidative stress is induced by an imbalanced redox states, involving either excessive generation of reactive oxygen species (ROS) or dysfunction of the antioxidant system. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Mammalian cells remove misfolded proteins using various proteolytic systems, including the ubiquitin (Ub)-proteasome system (UPS), chaperone mediated autophagy (CMA) and macroautophagy. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neuroinflammation and mitochondrial dysfunction are common features of chronic neurodegenerative diseases of the central nervous system. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The extracellular matrix (ECM) is a critical regulator of neural network development and plasticity. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cost estimates did not differ significantly between CN and MCI. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Diabetic patients have an elevated risk of dementia, and comorbidity increases this risk. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study provides evidence that the increase in dementia-free life years went together with an absolute compression of life years with dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Down syndrome (DS) is one of the commonest disorders with huge medical and social cost. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by loss of memory and cognitive abilities, and the appearance of amyloid plaques composed of the amyloid-β peptide (Aβ) and neurofibrillary tangles formed of tau protein. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our objective was to assess the validity of the Edinburgh Cognitive and Behaviour ALS Screen (ECAS), a multi-domain screen designed to detect cognitive deficits in patients with motor disorders. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
PET amyloid imaging is increasingly used in research trials related to Alzheimer disease and has potential as a quantitative biomarker. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Beta-site Amyloid precursor protein Cleaving Enzyme 1 (BACE1) is conceived as a potential target for therapies against Alzheimer disease (AD) which is characterized by the accumulation of plaques formed of short β-amyloid (APPβ) peptides. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Nasu-Hakola disease or polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) is a rare recessively inherited disease that is associated with early dementia and bone cysts with fractures. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is a complex age-related neurodegenerative disorder of the central nervous system. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Impaired insulin signaling pathway in the brain in type 2 diabetes (T2D) is a risk factor for Alzheimer disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Older adults living in rural areas may face barriers to obtaining a diagnosis of Alzheimer's disease and related disorders (ADRD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The level of technology use in the context of aging in place is influenced by six major themes: challenges in the domain of independent living; behavioral options; personal thoughts on technology use; influence of the social network; influence of organizations, and the role of the physical environment. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Age-related cataracts are frequently associated with degenerative changes in the ocular lens including the aggregation of proteins - mainly crystallins, but also other proteins including amyloids (Aβ) leading to the hypothesis that cataracts could be used as "biomarkers" for Alzheimer disease. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →